Danish Carvedilol Study in Portal Hypertension
Overview
Patients with large esophageal varices who have not yet experienced bleeding, are normally treated with propranolol, a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding. 20-40% of the patients do not respond to this treatment or have to discontinue the treatment because of side effects. The aim of this study is to evaluate if carvedilol (a combined alfa -beta blocker) has better efficacy and safety than propranolol in lowering the portal pressure in patients with cirrhosis.
Full Title of Study: “Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: August 2009
Interventions
- Drug: carvedilol
- 6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
- Drug: propranolol
- 80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
Arms, Groups and Cohorts
- Active Comparator: carvedilol
- Active Comparator: propranolol
- Cirrhotic patients treated with propranolol
Clinical Trial Outcome Measures
Primary Measures
- If carvedilol is better than propranolol in lowering portal pressure after 3 months of treatment
- Time Frame: 3 months
Secondary Measures
- If the effect of a single dose of propranolol can predict the long term effect of propranolol or carvedilol
- Time Frame: 3 months
Participating in This Clinical Trial
Inclusion Criteria
- Cirrhosis – HVPG > 12 mmHg Exclusion Criteria:
- Respiratory disease that contradict endoscopy – Hepatic encephalopathy – Hepatorenal syndrome – COPD or Asthma – Treatment with vasoactive drugs within 1 week of inclusion – Heart disease that contradict treatment with beta-blocking agents – IDDM – Pregnancy
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hvidovre University Hospital
- Provider of Information About this Clinical Study
- Erik Feldager/ sponsor, Erik Feldager, Hvidovre Hospital
- Overall Official(s)
- Erik F Hansen, MD,Ph.d, Principal Investigator,
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.